The genomic profile of HER2-amplified breast cancers: the influence of ER status.
about
Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biologyA gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of SykWnt signaling in triple negative breast cancer is associated with metastasisExploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models.Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer.Genome profiling of ERBB2-amplified breast cancers.Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform.Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.Polarity gene alterations in pure invasive micropapillary carcinomas of the breastHigh-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancerHER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.Genetic characterization of breast cancer and implications for clinical managementLandscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancerHuman epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?LIN7A is a major determinant of cell-polarity defects in breast carcinomasImmunophenotypic and genomic characterization of papillary carcinomas of the breast.Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas.Alternative lengthening of telomeres: recurrent cytogenetic aberrations and chromosome stability under extreme telomere dysfunction.DNA amplifications in breast cancer: genotypic-phenotypic correlations.The 11q13-q14 amplicon: clinicopathological correlations and potential drivers.Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies.Functional characterization of EMSY gene amplification in human cancers.Do 'basal-like' breast cancers really exist?Is there 'progression through grade' in ductal invasive breast cancer?Absence of estrogen receptor alpha (ESR1) gene amplification in a series of breast cancers in Taiwan.Application of a co‑expression network for the analysis of aggressive and non‑aggressive breast cancer cell lines to predict the clinical outcome of patients.Genomic profiling of histological special types of breast cancer.GRB7 protein over-expression and clinical outcome in breast cancer.
P2860
Q28269080-E2335E88-B241-4ED3-997F-BAB7B9444389Q30496002-2DF12386-886B-455B-BA11-C9AD2A8D8743Q30597238-88F9369C-C56A-4AC7-BDEE-86F09ACA7CC1Q33533301-F6E8C679-CAC1-4879-BB2B-8DE624CC3861Q33579776-31EE2762-5D23-421B-8CFE-394A58296B07Q33683344-5E6507C5-45ED-4FD3-86CC-3D5C69DFC8C6Q33713239-F8A0C279-A619-4773-92C4-1D3BBD03284DQ33776184-BB387264-FFCF-4B9C-9D18-DF1CE627E6E6Q33780945-D6EB07EF-3F6D-4EFD-96F9-FBA2F5097D84Q33892823-A55E182B-CF09-45F8-A1AB-69643B6615CCQ34048024-A7BCEF21-0D28-453A-B82D-B5E074D8F9DDQ34194672-1FF8B29B-17BF-49D4-BE52-4703511FD250Q34615545-59878A66-D334-472F-B6B4-61992BFBCAEAQ35633666-74371E00-E2F3-4C35-9B5E-BBF27EE68B42Q35832016-7701BDD4-E5DC-46EB-BBFE-2D0CE315B395Q35889655-159F53B3-3340-48AE-A806-E57AEB21DA67Q36551617-02C27378-C8F4-44B6-9B35-A69E20508CA7Q36588092-8156A90D-2D76-40F5-AD9E-14C75BE3185BQ37130628-4986BC0F-EE03-4FD2-9377-9967B5495289Q37345320-521710D4-EAC3-4F7B-B0FA-59DDDF816336Q37382517-6DE8D447-147E-4D5E-B56D-620E2E268E42Q37763102-B37E63D0-F449-4219-AB67-13CDB232B403Q38066149-23EB8FA1-8BBE-41E1-BFFC-9F8BC3E2A5CAQ38493679-519F2196-C2BA-4007-8B2A-3D2D3FAC51EDQ39207741-9B69822E-2334-4F80-9449-5A8DEBD7BC5AQ39511351-869E0606-4312-428D-92CA-A740ED8CFE20Q42447530-EF6045AD-B63F-48A3-B81D-42ABCCE2DA57Q42511105-02E16D26-0F45-4AA9-8364-5230ACB053E0Q44823361-4412F715-D6ED-461C-96AB-CE55A80F0A58Q47637451-3BE964B5-1073-4DD4-AA4F-CE556C1F6618Q53085136-9E0436AA-0803-418B-BEF2-95013223AB9CQ53464299-28F1B19F-A6BF-47F3-83CA-E7536B8C720F
P2860
The genomic profile of HER2-amplified breast cancers: the influence of ER status.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
The genomic profile of HER2-amplified breast cancers: the influence of ER status.
@en
type
label
The genomic profile of HER2-amplified breast cancers: the influence of ER status.
@en
prefLabel
The genomic profile of HER2-amplified breast cancers: the influence of ER status.
@en
P2093
P50
P356
P1476
The genomic profile of HER2-amplified breast cancers: the influence of ER status.
@en
P2093
D Hungermann
J Palacios
J S Reis-Filho
M B K Lambros
P304
P356
10.1002/PATH.2423
P577
2008-12-01T00:00:00Z